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Ferroportin is the primary means of cellular iron efflux
and a key component of iron metabolism. Hepcidin
regulates Fpn activity by inducing its internalization
and degradation. The mechanism of internalization is
reported to require JAK2 activation, phosphorylation
of Fpn tyrosine residues 302 and 303, and initiation
of transcription through STAT3 phosphorylation.
These findings suggest Fpn may be a target for thera-
peutic intervention through JAK2modulation. To eval-
uate the proposed mechanism, Fpn internalization
was assessed using several techniques combined
with reagents that specifically recognized cell-surface
Fpn. In vitro results demonstrated that Hepc-induced
Fpn internalization did not require JAK2 or phosphor-
ylation of Fpn residues 302 and 303, nor did it induce
JAK-STAT signaling. In vivo, inhibition of JAK2 had
no effect on Hepc-induced hypoferremia. However,
internalization was delayed by mutation of two Fpn
lysine residues that may be targets of ubiquitination.INTRODUCTION
Iron is essential for cell growth and proliferation as a component
of fundamental processes such as DNA replication and energy
production. The property that makes iron valuable for these
activities is its ability to cycle between ferrous and ferric oxida-
tion states at physiological pH. This property may also make
iron toxic to biological systems, as unregulated redox activity
confers the potential to generate highly reactive hydroxyl radi-
cals (Andrews, 1999). This dichotomy of iron’s required, yet
potentially dangerous, redox activity has led to the evolution of
tight controls over iron uptake and movement to minimize iron
deficiency, excess, or maldistribution.
Ferroportin (Fpn), the only recognized mammalian iron export
transporter, is highly expressed on the surface of both duodenalCenterocytes and macrophages. In the duodenum, Fpn facilitates
the transport of dietary iron into the bloodstream. In macro-
phages, it mediates export of iron recycled from senescent red
blood cells back into circulation. To export iron, Fpn must be
on the cell surface; therefore, understanding how localization
to the plasma membrane is controlled is critical to designing
therapeutic interventions to treat iron metabolism disorders.
Cell-surface Fpn expression is regulated by hepcidin (Hepc),
a 25 amino acid peptide produced in response to increased
body iron stores and inflammation (Nicolas et al., 2002). Hepc
binding to Fpn triggers Fpn internalization and degradation
(Nemeth et al., 2004). Chronic Hepc-mediated Fpn destabiliza-
tion and the associated reduction in plasma iron availability
may result in anemia. To treat Hepc-associated anemia, anti-
Hepc antibodies have been generated (Sasu et al., 2010); Fpn
may also be a target if a therapeutic means of preventing
Hepc-mediated internalization can be identified.
The mechanism of Fpn internalization has been understood to
require JAK2-mediated phosphorylation of Fpn tyrosine resi-
dues 302 and 303 (De Domenico et al., 2007). This internalization
is reportedly accompanied by a transcriptional response initi-
ated by JAK2-mediated phosphorylation of STAT3 (De Dome-
nico et al., 2009, 2010). Given the proposed role of JAK2 and
the availability of JAK2 inhibitors, therapeutic stabilization of
Fpn through JAK2 inhibition appeared feasible.
In this study, the role of JAK2 and requirement for phosphory-
lation of Fpn residues Y302 and Y303 in Hepc-induced Fpn
internalization were investigated. The in vitro analysis used
recently developed reagents that specifically detect surface-
expressed Fpn in combination with JAK2 inhibitors in both engi-
neered and native cell lines. JAK2 inhibitors were also evaluated
in vivo for their effect on Hepc-induced hypoferremia. The results
demonstrated that neither JAK2 nor phosphorylation of Fpn
residues 302 and 303 was required for Hepc-mediated internal-
ization. Furthermore, Hepc-mediated Fpn internalization did not
induce JAK-STAT signaling, nor was Fpn internalization affected
by JAK2 inhibitors. However, Hepc-induced internalization of
Fpn was significantly reduced by mutation of two intracellular
lysine residues of Fpn that may be ubiquitinated upon Hepc
binding.ell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 905
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Ferroportin-Specific Reagents Were Developed to
Assess Hepcidin-Mediated Ferroportin Internalization
To detect surface-expressed Fpn specifically, two classes of
reagents were developed: monoclonal anti-human Fpn anti-
bodies that recognize an epitope on the extracellular surface of
Fpn, and biologically active rhodamine green-labeled hepcidin
(RhoG-Hepc) that binds to and is internalized with cell-surface-
expressed Fpn. Specificity of the antibodies and RhoG-Hepc
was demonstrated using 293 T-REx cells expressing Fpn under
the control of a doxycycline-inducible promoter (293 T-REx/
Fpn). Each of the anti-human Fpn antibodies, two fully human
antibodies (H1, H2) and one mouse antibody (M1), detected
cell-surface Fpn on induced but not uninduced cells (Figure 1A).
Similarly, RhoG-Hepc uptake was only detected in induced cells
(Figure 1B). Quantitative assessment of both antibody binding
(Figure 1C) and RhoG-Hepc uptake (Figure 1D) was possible
through the use of an automated imaging platform where each
data point reflects the signal/cell for R300 cells. Because the
imaging and image analysis is automated, user bias is removed
from the measurement.
Antibody H1 was also used to detect Fpn by western analysis.
Fpn was observedmigrating with an apparent molecular mass of
65 kDa in lysates from induced 293 T-REx/Fpn cells but was not
detected in either uninduced cells or induced cells treated with
Fpn siRNA (Figure 1E).
Phosphorylation of Ferroportin Residues Y20, Y302,
Y303, and Y538Was Not Required for Hepcidin-Induced
Ferroportin Internalization
Hepc-induced Fpn internalization has been reported to require
phosphorylation of Fpn tyrosine residues 302 and 303 (De Do-
menico et al., 2007). To evaluate this finding, changes in surface
Fpn were assessed in 293 T-REx cells stably expressing either
wild-type (WT) Fpn or one of two Fpn tyrosine mutants: Y2F
(Y302F, Y303F) or Y4F (Y20F, Y302F, Y303F, Y538F). Tyrosines
20, 302, 303, and 538 represent all the tyrosines predicted to be
on the intracellular face of Fpn according to the topology model
of Liu et al. (Liu et al., 2005). Analysis of Y4F provided an inde-
pendent means of corroborating the Y2F results and determining
whether phosphorylation of tyrosines other than Y302 and Y303
was required for Fpn internalization. In induced cells, WT, Y2F,
and Y4F Fpn were detectable on the cell surface (Figure 2A).
Surface Fpn expression levels determined using a bead-based
flow cytometry assay indicated that expression levels for Y2F
and Y4F Fpn were 50% and 30%, respectively, relative to WT
Fpn. Iron export ability was confirmed for each of the Fpn
constructs by monitoring intracellular ferritin levels (see Fig-
ure S1A online). Although doxycycline, which is used to induce
Fpn expression, is a weak iron chelator, it would not be expected
to change the iron status of cells, as it is used at low concentra-
tions (10 ng/ml; 19 nM) and is removed prior to iron treatment
(10 mM). Uninduced cells (no Fpn expression) had high ferritin
levels in the presence of iron. Induced cells expressing WT,
Y2F, or Y4F Fpn had low levels of ferritin in the presence of
iron, as active Fpn on the cell surface allowed iron to move out
of the cell. Addition of Hepc toWT, Y2F, and Y4F Fpn-expressing
cells caused an increase in intracellular ferritin accumulation in906 Cell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc.the presence of iron. This provided the first indication that Y2F
and Y4F Fpn were both internalized in response to Hepc.
To characterize the response of WT, Y2F, and Y4F Fpn to
Hepc further, changes in surface and total Fpn were compared.
Surface Fpn was distinguished from total Fpn by comparing Fpn
staining in live cells versus fixed and permeabilized cells, respec-
tively. In live cells (Figures 2A–2D), Hepc treatment induced loss
of surface Fpn in cells expressingWT, Y2F, and Y4F Fpn (Figures
2A and 2B). Fpn internalization was quantified as a function of
time following Hepc treatment (Figure 2C) and Hepc concentra-
tion (Figure 2D). There was no statistically significant difference
in either the rate or extent of Hepc-induced internalization in cells
expressing WT, Y2F, or Y4F Fpn. Fpn internalization in all three
cell lines was corroborated by RhoG-Hepc uptake (Figures
S1B and S1C): accumulation of RhoG-Hepc was apparent in
induced WT, Y2F, and Y4F Fpn-expressing cells but not in unin-
duced cells. The RhoG-Hepc signal appeared intracellular and
punctate, consistent with uptake into vesicles. Collectively,
these results indicate that phosphorylation of tyrosine residues
20, 302, 303, and 538 was not required for Hepc-induced Fpn
internalization.
To evaluate the effect of Hepc on total Fpn rather than cell-
surface Fpn, Fpn staining was performed on fixed and permea-
bilized cells. Loss of total Fpn was observed after Hepc
treatment in WT Fpn-expressing cells; however, nearly all the
Fpn was still detectable in both Y2F and Y4F Fpn-expressing
cells (Figures 2E and 2F). This suggested that a portion of the
Y2F and Y4F Fpn proteins was intracellular and was not suscep-
tible to Hepc-mediated degradation. It also suggested that the
material that was internalized was not efficiently degraded after
3 hr. This may indicate the degradation pathway is overwhelmed
by the excessive Fpn present inside the cell. Western analysis of
lysates from WT versus Y2F and Y4F Fpn-expressing cells
corroborated the presence of two Fpn populations in the Y2F
and Y4F cell lines. In lysates from WT Fpn-expressing cells, an
64 kDa band was the primary band (Figure S1D). This band
disappeared upon Hepc treatment. In lysates from Y2F and
Y4F Fpn-expressing cells, two main bands were present: the
64 kDa band and another that migrated at 52 kDa. After 6 hr
of Hepc treatment, the 64 kDa band is reduced, consistent
with Hepc-mediated internalization and degradation; however,
the 52 kDa band was not affected by Hepc treatment. The Y2F
and Y4F Fpn lysates contained additional bands migrating
above 64 kDa, suggesting the presence of aggregates. Further
evidence that Y2F and Y4F Fpn may be retained inside the cell
comes from colocalization studies evaluating Fpn and an endo-
plasmic reticulum-specific marker (KDEL). Detectable quantities
of intracellular Fpn colocalized with KDEL in the Y2F and Y4F
Fpn-expressing cells but not in theWT Fpn-expressing cells (Fig-
ure S1E). Together these results suggest that a portion of Y2F
and Y4F Fpn does not progress to the cell surface, perhaps
due to incorrect folding or inability to interact with chaperones,
and is inaccessible to Hepc. However, the portion of Y2F and
Y4F Fpn that does traffic to the cell surface responded to Hepc.
JAK2 Expression Was Not Required for
Hepcidin-Induced Ferroportin Internalization
Hepc-induced Fpn internalization has been reported to require
JAK2 expression (De Domenico et al., 2009). To evaluate this
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Figure 1. Reagent Specificity Was Demonstrated by Immunofluorescence and Western Analysis
(A) Immunofluorescence: uninduced (top panel) and induced (bottom panel) live 293 T-REx/Fpn cells were probed with Fpn antibodies H1, H2, and M1.
(B) RhoG-Hepc uptake: uninduced (top panel) and induced (bottom panel) live 293 T-REx/Fpn cells were treated with RhoG-Hepc for 60 min.
(C) Cell-surface Fpn was quantified in uninduced and induced 293 T-REx/Fpn cells as described in the Experimental Procedures (mean ±SD, n = 6).
(D) Intracellular RhoG-Hepc was quantified following 60 min treatment (mean ±SD, n = 3 for uninduced cells, n = 6 for induced cells).
(E) Western analysis: uninduced or induced 293 T-REx/Fpn cells were treated with transfection reagent alone (siRNA) or transfected with Fpn (Fpn), non-
silencing (NS), or cyclophilin B (Cyp) siRNA for 48 hr, followed by western analysis with antibody H1. Cyclophilin was used as a loading and transfection efficiency
control.
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Mechanism of Ferroportin Internalizationfinding, Fpn was expressed in JAK2 null human fibrosarcoma
g2A cells, which are reported to have undetectable levels of
JAK2 mRNA and protein (Kohlhuber et al., 1997). Absence ofCJAK2 protein in g2A cells was confirmed by western analysis
(Figure S2A). Surface Fpn was detected on live g2A cells stably
transfected with Fpn (g2A/Fpn), and this Fpn was decreasedell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 907
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Figure 2. WT and Tyrosine Mutant Fpn Proteins Were Responsive to Hepc
(A) 293 T-REx cells expressing WT or mutant (Y2F, Y4F) Fpn were treated with control medium or 1 mM Hepc for 180 min. Cell-surface Fpn was detected on live
cells with Fpn antibody H1 and (B) quantified with image analysis (mean ±SD, n = 3). Loss of cell-surface WT and mutant Fpn, detected with antibody M1, was
quantified in cells treated with either (C) 250 nM Hepc over time (n = 18, three independent experiments) or (D) a dose range of Hepc for 3 hr (n = 12, three
Cell Metabolism
Mechanism of Ferroportin Internalization
908 Cell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc.
A293 T-REx/Fpn 
- Hepc + Hepc
Cells
2A/Fpn Cells
50 µm
100
150
293 T-REx/Fpn
2a/Fpnce
 F
pn
ea
/C
el
l)
B
60
80
100
293 T-REx/Fpn
ce
 F
pn
a/
C
el
l)
C
0 100 200 300 400
0
50
Time (min)
C
el
l S
ur
fa
(P
ix
el
 A
re
-11 -10 -9 -8 -7 -6 -5
0
20
40
Log [Hepc] (M)
C
el
l S
ur
fa
(P
ix
el
 A
re
2a/Fpn
Figure 3. Fpn Internalization Was Observed in Response to Hepc in JAK2 Null Cells
(A) 293 T-REx/Fpn cells and JAK2 null g2A/Fpn cells were induced to express Fpn, treated with control medium or 1 mMHepc for 3 hr. Live cells were stained with
Fpn antibody H1. Loss of cell-surface Fpn was quantified in 293 T-REx/Fpn cells and g2A/Fpn cells (B) over time after treatment with 250 nM Hepc and (C) over
a dose range of Hepc. Fpn was detected with antibody H2. Data shown are mean ±SD, n = 4. See also Figure S2.
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Mechanism of Ferroportin Internalizationupon treatment with Hepc (Figure 3A). Quantification of Hepc-
induced Fpn internalization, both as a function of time of Hepc
treatment (Figure 3B) and Hepc concentration (Figure 3C),
demonstrated that Fpn expressed in g2A cells was internalized
similarly to Fpn expressed in 293 T-REx cells. Surface Fpn
expression was less in g2A/Fpn cells than in 293 T-REx/Fpn, ex-
plaining the difference in the starting cell-surface fluorescence.
The observed delay in the initiation of internalization in the
g2A/Fpn cells is likely due to experimental variation, but it may
also reflect a slower initial endocytosis rate in this cell line. It is
unlikely to indicate a requirement for JAK2, as loss of cell-surface
Fpn at later time points is similar to that observed for 293 T-REx/independent experiments). Data shown are mean ±SD. No statistically significant
(p range = 0.06–0.9 for Y2F and 0.07–0.4 for Y4F) or anyHepc concentration (p ran
mutant (Y2F, Y4F) Fpn were treated as described for (A). Total Fpn was detected
image analysis (mean ±SD, n = 3). See also Figure S1.
CFpn cells, and the Hepc dose-response profiles of the two cell
lines are also similar (EC50 = 5 and 11 nM for 293 T-REx and
g2A, respectively). Western analysis confirmed that Hepc
treatment induced Fpn degradation in g2A cells (Figure S2B).
Together these results demonstrated that JAK2 expression was
not required forHepc-inducedFpn internalizationor degradation.
Hepcidin-Induced Ferroportin Internalization Did Not
Induce JAK-STAT Signaling
Phosphorylation of JAK2 and STAT3 has been reported to be
induced by Hepc/Fpn interaction (De Domenico et al., 2010).
JAK-STAT activation was evaluated following Hepc treatmentdifferences were observed between WT and Y2F or Y4F Fpn at any time point
ge = 0.3–0.9 for Y2F and 0.06–0.9 for Y4F). (E) 293 T-REx cells expressingWT or
in fixed and permeabilized cells using Fpn antibody H1 and (F) quantified with
ell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 909
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Mechanism of Ferroportin Internalizationof 293 T-REx/Fpn cells and in two cell lines that express Fpn
endogenously: T47D, a ductal breast epithelial tumor cell line,
and UT-7/Epo, an erythropoietin (Epo)-dependent leukemia
cell line. All three cell lines expressed surface Fpn that was inter-
nalized and degraded upon Hepc treatment (Figures S3A and
S3B). Hepc-induced JAK-STAT activation was assessed using
two readouts: western analysis of phospho-JAK2, phospho-
STAT3, and/or phospho-STAT5 and nuclear translocation of
either phospho-STAT3 or phospho-STAT5. As a positive control,
each cell line was treated with a cytokine that activated the
JAK-STAT pathway. Translocation assays were used to obtain
quantitative results over wide Hepc and control cytokine
concentration ranges. Previous reports indicate that Hepc-
induced phospho-JAK2 and phospho-STAT3 are detectable
30 min after treatment (De Domenico et al., 2009, 2010), hence
the same time point was analyzed here. Positive control cyto-
kines used were IL-6/sIL-6Ra for 293 T-REx/Fpn cells (293 cells
express IL-6 receptor) (Leung et al., 2003), prolactin (PRL) for
T47D cells (T47D cells express PRL receptor) (Nouhi et al.,
2006), and Epo for UT-7/Epo cells (UT-7/Epo cells express
Epo receptor) (Erickson-Miller et al., 2000). Each of the positive
control cytokines induced phospho-JAK2, phospho-STAT3
and/or phospho-STAT5 as reported: IL-6 receptor stimulation
activated phospho-JAK2 and phospho-STAT3 (Figures 4A and
4B and Guschin et al., 1995), PRL receptor stimulation activated
phospho-JAK2 and -STAT5 (Figures 4C and 4D and Nouhi et al.,
2006), and Epo receptor stimulation activated phospho-JAK2,
phospho-STAT3, and phospho-STAT5 (Figures 4E and 4F, Fig-
ure S3C, and Kirito et al., 1997). In contrast, Hepc treatment
did not induce phospho-JAK2, phospho-STAT3, or phospho-
STAT5 at any of the analyzed time points in any of the cell lines
(Figures 4A–4F, Figure S3C). These results demonstrated, using
two different assays in cell lines expressing both exogenous and
endogenous Fpn, that Hepc treatment did not induce phosphor-
ylation of JAK2, STAT3, or STAT5, although Hepc treatment did
induce Fpn internalization and degradation in each of the cell
lines (Figures S3A and S3B).
JAK Inhibitors Did Not Prevent Hepcidin-Induced
Ferroportin Internalization In Vitro
To evaluate the reported requirement for JAK2 in Hepc-induced
Fpn internalization (De Domenico et al., 2009, 2010), the effect of
a pan-JAK and a JAK2-selective inhibitor on Hepc-induced Fpn
internalization was characterized in 293 T-REx/Fpn, T47D, and
UT-7/Epo cells. Selectivity of these inhibitors against JAK family
members was characterized by JAK enzyme inhibition (Table
S1). Activity of these inhibitors in 293 T-REx/Fpn, T47D, and
UT-7/Epo cells was demonstrated by a dose-dependent inhibi-
tion of phospho-STAT translocation in response to IL-6/sIL-
6Ra, PRL, and Epo, respectively (Figure 5A). Despite this, there
was no effect on Hepc-induced internalization of Fpn as deter-
mined by monitoring surface Fpn expression (Figure 5B). As
a positive control to demonstrate small-molecule-mediated
protection against Hepc-induced Fpn internalization, cells were
treated with a thiol-reactive small molecule that prevented
Hepc-induced Fpn internalization (Figure 5B). The thiol-reactive
small molecule likely reacts with Fpn residue C326 to prevent the
Hepc/Fpn interaction, as has been demonstrated previously for
other thiol-reactive compounds (Fernandez et al., 2009). The910 Cell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc.thiol-reactive compound had no effect on JAK2 activity (Fig-
ure 5A). Together these results demonstrated that JAK inhibitors
did not prevent Hepc-mediated Fpn internalization in either engi-
neered or native Fpn-expressing cell lines.
JAK Inhibitors Did Not Prevent Hepcidin-Induced
Ferroportin Internalization In Vivo
To evaluate the requirement for JAK2 activity in Hepc-induced
Fpn internalization in vivo, mice were treated with Hepc in the
presence or absence of either a pan-JAK or JAK2-selective
inhibitor at a dose previously determined to inhibit JAK2 effec-
tively in vivo (Liu et al., 2011), and plasma iron was measured
90 min later. The JAK inhibitors were shown to be active at the
90 min time point using a whole-blood Phosflow assay that
detects the presence of phospho-STAT5 in granulocyte macro-
phage colony-stimulating factor (GM-CSF)-stimulated granulo-
cytes/monocytes. For this assay, whole blood was collected
from each control and treatment group of mice and treated
ex vivo with GM-CSF. GM-CSF has been reported to induce
JAK2 and phospho-STAT5 in granulocytes/monocytes (Al-
Shami et al., 1998). GM-CSF treatment of cells from naive
(untreated) mice resulted in a significant increase in phospho-
STAT5. In cells from mice treated with either the pan-JAK or
JAK2-selective inhibitor, there was complete suppression of
phospho-STAT5 in response to GM-CSF (Figure 6A), indicating
that the concentration of JAK inhibitors at this time point
was sufficient to inactivate JAK2 completely. As previously
described, Hepc treatment of mice causes Fpn internalization,
resulting in decreased iron efflux from cells and a net reduction
in plasma iron (Rivera et al., 2005). In the current study, mice
treated with Hepc and either vehicle, pan-JAK inhibitor, or
JAK2-selective inhibitor all had a significant reduction in plasma
iron concentration at the 90 min time point (Figure 6B). Mice
treated with Hepc and a neutralizing anti-Hepc antibody did
not have a reduction in plasma iron concentration. These results
agreed with the in vitro data presented, confirming that JAK2
activity was not required for Hepc-induced Fpn internalization.
Ferroportin Lysines 240 and 258 Were Required
for Hepcidin-Induced Ferroportin Internalization
The published mechanism of Hepc-induced Fpn internalization
indicates the following: Fpn phosphorylation triggers Fpn inter-
nalization, and intracellular phosphorylated Fpn is dephosphory-
lated, ubiquitinated, and routed for degradation. In this model,
ubiquitination marks Fpn for degradation (De Domenico et al.,
2007). To evaluate the possibility that ubiquitination may be the
trigger for Hepc-induced Fpn internalization in place of phos-
phorylation, systematic mutation of an intracellular lysine-rich
region was undertaken by Qiao et al. (2012 [this issue of Cell
Metabolism]), and several lysine mutants were identified that
were resistant to Hepc. An inducible 293 T-REx cell line was
made representing one such resistant mutant in which lysine
residues 240 and 258 were mutated to arginine, referred to
here as K2R. K2R Fpn was detected on the surface of induced
cells (Figure 7A) and was shown to be competent to export
iron as determined by intracellular ferritin levels (Figure 7B).
Surface Fpn expression level of K2R Fpn-expressing cells,
determined using a bead-based flow cytometry method, was
190%, relative to WT Fpn-expressing cells. Hepc treatment
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Figure 4. Hepc Treatment Did Not Induce JAK2-STAT Signaling
(A) Induced 293 T-REx/Fpn cells were treated with control medium (CM), 500 nM Hepc (Hepc), or 9.8 nM rHu IL-6 + 26.3 nM soluble rHu IL-6Ra (IL-6) for 30 and
360 min. Lysates were immunoblotted with phospho-JAK2 and phosopho-STAT3 antibodies.
(B) Induced 293 T-REx/Fpn cells were treated with a dose response of either IL-6 or Hepc for 30 min. Nuclear phospho-STAT3 was quantified using image
analysis (mean ±SD, n = 3).
(C) Serum-starved T47D cells were treated with control medium (CM), 10 nM rHu prolactin (PRL), or 500 nMHepc (Hepc) for 30 and 360 min. Lysates were
immunoblotted with phospho-JAK2 and phospho-STAT5 antibodies.
(D) Serum-starved T47D cells were treated with a dose response of PRL or Hepc for 30 min. Nuclear phospho-STAT5 was quantitated with image analysis
(mean ±SD, n = 4).
(E) Epo-starved UT-7/Epo cells were treated with control medium (CM), 0.28 nM rHuEpo (Epo), or 1 mMHepc (Hepc) for 15, 30, 60, 180, or 360 min. Lysates were
immunoblotted with phospho-JAK2 and phospho-STAT5 antibodies.
(F) Epo-starved UT-7/Epo cells were treated with a dose response of Epo or Hepc for 30 min. Nuclear phospho-STAT5 was quantified with image analysis
(mean ±SD, n = 4). Cyclophilin was used to confirm protein load for all western analyses. See also Figure S3.
Cell Metabolism
Mechanism of Ferroportin Internalizationinduced less internalization of K2R than WT Fpn (Figure 7A).
Quantification of Hepc-induced Fpn internalization, both as a
function of time of Hepc treatment (Figure 7C) and Hepc concen-Ctration (Figure 7D), demonstrated that K2R Fpn internalization
was significantly reduced compared to WT Fpn. A difference in
RhoG-Hepc uptake between WT and K2R Fpn-expressing cellsell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 911
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Figure 5. JAK2 Inhibitors Did Not Prevent Hepc-Mediated Fpn Internalization
(A) STAT3/5 nuclear translocation assays were used to demonstrate JAK inhibitor activity. Cell treatment prior to stimulation was as follows: 293 T-REx/Fpn cells
were induced overnight with doxycycline; T47D and UT-7/Epo cells were both treated with iron and starved of serum and Epo, respectively. All cells were treated
with a dose response of three different small molecules (JAK2-selective inhibitor, pan-JAK inhibitor, or thiol-reactive small molecule) for 30 min prior to the
addition of IL-6 (293 T-REx/Fpn cells), rHuPRL (T47D cells), or rHuEpo (UT-7/Epo cells) for 30 min at the same concentrations used in Figures 4A, 4C, and 4E.
Nuclear phospho-STAT3 (293 T-REx/Fpn cells) and phospho-STAT5 (T47D and UT-7/Epo cells) were detected with phospho-specific antibodies.
(B) Cells were induced overnight with either doxycycline (293 T-REx/Fpn cells) or iron (T47D cells and UT-7/Epo cells). Cells were then treated with small
molecules (JAK2-selective inhibitor, pan-JAK inhibitor, or thiol-reactive small molecule) for 30 min prior to the addition of 250 nMHepc (293 T-REx/Fpn and T47D
cells) or 500 nMHepc (UT-7/Epo cells) for 3 hr. Cell-surface Fpn was detected on live cells with Fpn antibody H1 (293 T-REx/Fpn and T47D cells) or H2 (UT-7/Epo
cells). Dotted lines represent positive and negative controls (+/ cytokine control in A and/+ Hepc in B, respectively). Data shown aremean ±SD, n = 3, 4, or 4 for
JAK inhibitors; n = 2, 4, or 4 for thiol-reactive small molecule (293 T-REx/Fpn, T47D, and UT-7/Epo cells, respectively). See also Table S1.
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Figure 6. JAK Inhibitors Did Not Prevent
Hepc-Mediated Hypoferremia In Vivo
Mice were dosed for 15 min with either a JAK2-
selective or pan-JAK small molecule inhibitor
(100 mg/kg, PO) or vehicle control prior to i.p.
administration of 50 mg Hepc or carrier control. (A)
JAK inhibitor activity was confirmed in an ex vivo
whole blood assay detecting GM-CSF-mediated
phosphorylation of STAT5.Whole blood harvested
from mice in each treatment group was treated
with 1 ng/mL mouse GM-CSF for 30 min. Phos-
pho-STAT5 was detected by flow cytometry. (B)
Plasma iron was measured 90 min after Hepc
administration. An inhibitory anti-Hepc antibody
(2 mg) was used as a positive control and was
dosed 24 hr before Hepc. Data represent
mean ±SEM, n = 5, except for the JAK2 inhibitor/
carrier group, where n = 1, and the naive group,
where n = 3. Statistics: *p < 0.05, ***p < 0.001 (one-
way ANOVA, Dunnett’s post-test using vehicle/
carrier as a comparator; JAK2 inh/carrier excluded
from statistics due to n = 1). See also Table S1.
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Mechanism of Ferroportin Internalizationwas also observed (Figure 7A). In cells expressing WT Fpn, the
RhoG-Hepc appeared intracellular and punctate; in cells ex-
pressing K2R Fpn, much of the RhoG-Hepc appeared to be
associated with the cell surface. The relative resistance of K2R
Fpn to Hepc was corroborated bymonitoring the degree of intra-
cellular ferritin accumulation following Hepc treatment. Ferritin
begins accumulating once iron can no longer move out of the
cell; however, >14 hr are required to ensure enough ferritin is
present for reliable quantitation. Following Hepc treatment, cells
expressing K2R Fpn accumulated significantly less ferritin than
cells expressing WT Fpn (Figure 7B), indicating that K2R Fpn
remains active on the cell surface longer than WT Fpn. However,
when ferritin accumulation in K2R Fpn cells treated with Hepc
was compared to K2R Fpn cells not treated with Hepc, it was
observed that Hepc treatment caused more ferritin to accumu-
late. This suggested that K2R Fpn internalization was slowed
but not completely inhibited over this time frame. There are
several other Fpn lysines predicted to be intracellular; it is
possible that other lysines can be ubiquitinated and induce inter-
nalization in this K2R mutant. The role of ubiquitination in Hepc-
induced Fpn internalization is further explored in the companion
manuscript by Qiao et al. (2012).
DISCUSSION
Understanding the mechanism of Hepc-mediated Fpn internali-
zation is critical for developing therapeutics to treat various iron
metabolism disorders. The experiments described here were
initiated with the intention of building on the proposed model
that Hepc-induced Fpn internalization requires Fpn phosphory-
lation and JAK2 activity. The prospect of a kinase as a drug
target and the ability to monitor Fpn phosphorylation as an indi-
cator of drug activity was compelling. However, repeated
attempts to reproduce the published results were unsuccessful
despite the use of similar experimental systems and readouts.
Key results from the pioneering study by De Domenico et al.
(De Domenico et al., 2007) showing a requirement for Fpn phos-
phorylation prior to internalization include Hepc-induced FpnCphosphorylation (detectable for 15–60 min after Hepc treat-
ment), persistence of cell-surface Fpn (Y302F/Y303F)-GFP in
the presence of Hepc (surface expression unchanged for 4 hr),
and absence of Hepc-induced Fpn(Y302F/Y303F)-GFP degra-
dation (level unchanged after 24 hr of Hepc exposure). These
experiments used HEK293T cells transiently transfected with
WT mouse Fpn-GFP or mutant Fpn-GFP, or the same cells
expressing mouse WT Fpn regulated by an ecdysone promoter.
In an attempt to reproduce the published results, human Fpn
with the same mutations was introduced into the same parental
cell line, and the response to Hepc was evaluated using similar
readouts. Differences between the experimental systems
include the Fpn species (mouse versus human), GFP (tagged
versus untagged), and means of Fpn induction (transient
transfection or ecdysone induction versus doxycycline induc-
tion). While it is possible that mouse Fpn behaves differently
than human Fpn, it was reported previously (De Domenico
et al., 2007) that Fpn phosphorylation ‘‘was independent of the
mode of Fpn expression (inducible versus transient/CMV) or
epitope [tag].’’
Contrary to published results, we found that phosphorylated
Fpn was not detected by western analysis (the same phospho-
tyrosine antibody was used, data not shown), >90% of the WT
and tyrosine mutant surface Fpn was internalized within 2 hr of
Hepc treatment, and notable degradation of WT and tyrosine
mutants occurred within 6 hr of Hepc treatment. A possible
explanation for the earlier interpretation that Fpn (Y302F/
Y303F) was resistant to Hepc is the means of Fpn detection.
De Domenico et al. evaluated total Fpn (Fpn-GFP) and relied
on visual assessment to determine Fpn localization. As demon-
strated here, mutation of Y302 and Y303 to phenylalanine re-
sulted in Fpn that was poorly expressed on the cell surface, likely
due to formation of nonproductive folding intermediates. As
a result, only a fraction of the total mutant Fpn was expressed
on the cell surface, but the Fpn that did traffic to the plasma
membrane was internalized in response to Hepc. Without a reli-
able and statistically robust means of distinguishing surface from
total Fpn, mutant Fpn may appear to be nonresponsive to Hepc.ell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 913
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Figure 7. Hepc-Induced Fpn Internalization Was Reduced in Fpn Lysine Mutant K2R
(A) 293 T-REx cells expressingWT or lysinemutant (K2R) Fpnwere treatedwith control medium, 250 nMHepc for 120min, or 250 nMRhoG-Hepc for 60min. Cell-
surface Fpn was detected on live cells with Fpn antibody H1. (B) 293 T-REx cells expressing WT or mutant (K2R) Fpn were treated for 16 hr ±10 mM ferric citrate
and ±2.5 mM Hepc and quantified with image analysis (mean ± SD, n = 4). Intracellular ferritin was significantly less in cells expressing K2R Fpn relative to WT
(p = 0.02). Loss of cell-surface WT and K2R Fpn, detected with Fpn antibody M1, was quantified in cells treated with either (C) 250 nM Hepc over time (n = 18,
3 independent experiments) or (D) a dose range of Hepc for 3 hr (n = 12, 3 independent experiments). Data shown are mean ±SD. Statistically significant
differences were observed for all time points after 30 min and all concentrations above 15 nM (p < 0.005) when compared to WT Fpn.
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Mechanism of Ferroportin InternalizationSubsequent publications reported that JAK2 was required for
Hepc-induced Fpn internalization (De Domenico et al., 2009,
2010). Supporting data included observations that Hepc-medi-
ated Fpn internalization was absent in JAK2 null g2A cells
transiently transfected with Fpn-GFP (surface localization
unchanged for 24 hr), HEK293T-Fpn-GFP cells and mouse
macrophages treated with JAK2 siRNA (surface localization
unchanged for 1 hr), and HEK293T-Fpn-GFP cells treated with
PP2, a small molecule SRC kinase inhibitor that is also a weak
inhibitor of JAK2 (Hanke et al., 1996) (surface localization
unchanged for 20 min). The same publications reported a direct
interaction between Fpn and phosphorylated JAK2 and STAT3.
We expressed Fpn in the same JAK2 null cell line (g2a) and
characterized it using similar assay readouts. Contrary to pub-
lished results, no reduction in Hepc-mediated Fpn internalization
was observed. Internalization in 293 T-REx/Fpn cells was also
unaffected by PP2 treatment (data not shown), again in contrast
with published data. The experiment was then repeated with
a more potent, cell-penetrant JAK2-specific inhibitor as well as
a pan-Jak inhibitor to determine whether other JAK family
members might be required for Hepc-mediated Fpn internaliza-
tion. Neither inhibitor reduced internalization, despite inhibiting
IL-6-induced JAK2 signaling. To eliminate possible anomalies
stemming from the use of an engineered cell line, human cell
lines expressing endogenous Fpn (UT7/Epo and T47D) were
treated with the JAK2 and pan-JAK inhibitors. As observed in
the 293 T-REx/Fpn cells, Fpn was internalized in response to
Hepc, although the inhibitors eliminated Epo- and PRL-induced
JAK2 signaling. To extend these results, the effect of JAK inhib-
itors on Fpn internalization was tested in vivo. Neither JAK2 nor
pan-JAK inhibitor treatment of mice affected the Hepc-induced
decrease in plasma iron despite the fact that both inhibitors
were shown to be effective at the time of analysis. While it is
possible that JAK2 may play a minor role in Hepc-mediated
Fpn internalization, the results presented here clearly indicate
that JAK2 is not required for Fpn internalization in vitro or in vivo.
Attempts to coimmunoprecipitate Fpn and phosphorylated
JAK2 were also unsuccessful (data not shown). In an effort to
troubleshoot this negative result, cells were treated with Hepc
or control cytokines and then analyzed for the presence of
phospho-JAK2, phospho-STAT3, or phospho-STAT5. Hepc
treatment did not induce phosphorylation of JAK2, STAT3, or
STAT5 in 293 T-REx/Fpn, UT7/Epo, or T47D cells despite the
fact that Fpn was internalized.
It is difficult to reconcile the findings by DeDomenico et al. with
those presented here, as the cell lines, Fpn constructs, and
experimental approaches were similar. While our studies do
not completely rule out some contribution of phosphorylation
to the effects of Hepc on Fpn, they demonstrate that JAK2-
mediated phosphorylation is not required for Hepc-induced
internalization and degradation.
Although a role for Fpn tyrosines in Hepc-induced internaliza-
tion was not found, mutation of Fpn lysines 240 and 258 to
arginine significantly reduced responsiveness to Hepc. The
mutations affected neither Hepc/Fpn binding nor Fpn iron export
activity. These lysines are predicted to be intracellular and
localize to a lysine-rich region of Fpn, and may be ubiquitinated
following Hepc binding to Fpn. Ubiquitination of transporters,
channels, and receptors has been reported to regulate endocy-Ctosis in yeast and mammalian cells (Rotin et al., 2000) and may
serve as a signal for Fpn internalization. The requirement for
ubiquitination is further evaluated in the companion manuscript
by Qiao et al. (2012). The sum of these results indicates that
JAK2 is not a rational therapeutic target to prevent Hepc-medi-
ated changes in iron metabolism. Further characterization of
this pathway is required to determine if there are other tractable
targets beyond targeting Hepc or Fpn directly.
EXPERIMENTAL PROCEDURES
Ferroportin Constructs and Cell Line Generation
Human Fpn (FPN, GenBank accession number BE554084) was cloned from
a Marathon-Ready Human Spleen cDNA collection (Clontech). Mutations
(Y20F, Y302F, Y303F, Y538F, K240R, K258R) were introduced using primer-
mediated mutagenesis and PCR. WT and mutant Fpn constructs (open
reading frame only) were cloned into pENTR1A vector (Invitrogen) and recom-
bined with a lentiviral vector containing a tetracycline-regulated promoter
using Gateway Technology (Invitrogen). Lentivirus was generated by cotrans-
fecting 293 cells with the lentiviral Fpn constructs and packaging plasmids.
Virus was harvested at 72 hr posttransfection and concentrated. 293 T-REx
(Invitrogen) and g2A/Fpn (Cancer Research Technology Ltd.) cells were trans-
duced with Fpn construct-containing viral particles and selected. g2A cells
were also transduced with a Tet repressor construct. All cell lines were derived
from single-cell clones, with the exception of the lysine K2R mutant, which
was used as a selected pool. DNA was isolated and resequenced following
selection of clones expressing Fpn Y2F and Y4F.
Cell Culture
Growth media are as follows: 293 T-REx cell lines and g2A cells, DMEM
(GIBCO), 10% fetal bovine serum (FBS, GIBCO), penicillin/streptomycin/
glutamine (PSQ, GIBCO), selective antibiotics; T47D cells, RPMI (GIBCO),
10% FBS, PSQ, 0.01 mg/mL bovine insulin (Sigma); and UT-7/Epo cells, an
Epo-dependent subline of the leukemia UT-7 cell line (Komatsu et al., 1993),
IMDM (GIBCO), 10% FBS, PSQ, 142 pM human Epo (rHuEpo, Amgen). Fpn
expression was induced in 293 T-REx cell lines and g2A cells using DMEM
containing 10% dialyzed FBS (GIBCO), 10 mM ferric citrate (Sigma), and doxy-
cycline (Clontech) at 10 ng/mL (293 T-REx cell lines) or 1 mg/mL (g2A cells).
Fpn expression was increased in T47D using 30 mM ferric citrate or 10 mM
iron NTA and in UT-7/Epo cells using 25 mM ferric citrate for 16 hr. Prior to
rHuEpo stimulation, cells were deprived of rHuEpo for 18 hr.
Anti-Ferroportin and Anti-Hepcidin Antibodies
Fully human anti-human Fpn antibodies (H1 and H2) were generated using
XenoMouse: mice engineered to express germline-configured human IgH
and IgGk loci, including most of their variable regions as well as the entire
Igl locus on a genetic background incapable of expressing murine immuno-
globulin (Mendez et al., 1997). Membranes from HEK293-6E cells expressing
Fpn using pTT5 plasmid (cells and plasmid licensed from the National
Research Council of Canada Biotechnology Research Institute) were used
as immunogen. Hybridomas were generated using standard techniques and
selected for Fpn binding. Mouse anti-human Fpn antibody M1 was generated
by immunizing C57BL/6 mice (Charles River Laboratory) with an adenovirus
expressing human Fpn and boosted with Fpn DNA as described in the pub-
lished international patent application WO 2009/094551 A1. Fully human
anti-humanHepc antibodies were generated in XenoMouse. The immunization
and selection techniques were similar to those described previously (Sasu
et al., 2010).
Synthetic Human Hepcidin and Rhodamine Green-Labeled Hepcidin
Synthesis
Hepc was synthesized and folded as described (Zhang et al., 2010). An amino-
hexanoic spacer was attached to the ε-amine of lysine of synthetic Hepc,
and RhoG carboxylic acid succinimidyl ester hydrochloride (Invitrogen) was
coupled overnight. Side chains were deprotected, and RhoG-Hepc was
refolded and purified as described for unlabeled Hepc.ell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc. 915
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Cells were induced as described above. Induction medium was replaced with
assay medium: DMEM/10% dialyzed FBS (for 293 T-REx cells) or growth
medium (for all other cell lines) containing Hepc. Cells were incubated at
37C for 180 min with varying concentrations of Hepc for dose-response
assaysorwith 250nMHepc for timecourse assays. For cell-surfaceFpndetec-
tion, Hepc-containingmediumwas replacedwith 2 mg/ml anti-human Fpn anti-
bodies (M1, H1 or H2) in cold assay medium, incubated for 1 hr, washed twice,
and incubated for 1 hr with secondary antibodies (goat anti-mouse-Alexa Fluor
647 or goat anti-human-Alexa Fluor 647, Invitrogen) and Hoechst 33342
nuclear dye (Invitrogen). After staining, cells were fixed with 3.7% formalde-
hyde solution (Sigma) for 10 min at room temperature, washed with phos-
phate-buffered saline (PBS, GIBCO), and imaged. For total Fpn staining, cells
were fixed with 3.7% formaldehyde solution and permeabilized with 0.1%
saponin (Calbiochem) and 1% bovine serum albumin (Sigma) in PBS at room
temperature. Fpn staining and imaging were completed as described above
except that the incubations were performed at room temperature.
Rhodamine Green-Labeled Hepcidin Uptake
293 T-REx cells expressing WT or mutant Fpn were induced as described or
left uninduced as controls. Cells were treated with 250 nM RhoG-Hepc for
60 min and fixed with 3.7% formaldehyde. Nuclei were stained with Hoechst
dye and imaged, and intracellular Hepc was quantitated. Uninduced (non-
Fpn-expressing) cells served as a negative control.
Cellular Imaging
Fluorescently labeled cells were imaged and quantitated using Cellomics
ArrayScan VTI Spot Detector (surface and total Fpn, Hepc uptake, and ferritin
assays) and NucTrans (STAT translocation assays) Bioapplications (Thermo-
Fisher). Spot Detector is an image analysis algorithm that detects signal above
local background as spots using an intensity threshold. Total spot (pixel) area
per cell = total pixel area above threshold/total nuclei. The NucTrans image
analysis algorithm detects target (STAT) fluorescence intensity differences
between the cytoplasmic and nuclear regions. Nuclear translocation (mean
nuclear intensity) = difference in fluorescent pixel intensities between the
nuclear and cytoplasmic regions/cell. Data represent averages for a minimum
of 300 cells/condition.
Quantitative Analysis of Cell-Surface Ferroportin Expression Level
Quantitative fluorescence cytometry was used to compare relative Fpn
expression levels in cell lines expressing WT and mutant Fpn according to
themanufacturer’s protocol (Quantum Simply Cellular kit, Bangs Laboratories,
Inc). Microspheres with increasing amounts of anti-mouse capture antibody
and Alexa Fluor 488-conjugated anti-Fpn antibody M1 (5 mg/mL) were used
to generate a standard curve. The same antibody was used to label 2 3 106
cells following the manufacturer’s protocol. Antibody binding capacity values
from uninduced cells were used as controls and were subtracted from values
for induced cells prior to regression analysis.
Western Blots
Cells were lysed in 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1%Triton X-100 with protease and phosphatase inhibitors (NaF, Roche
protease inhibitor, and Sigma phosphatase inhibitors I and II). Protein was
quantitated using a BCA protein assay (ThermoFisher). For Fpn analysis, non-
reduced lysates were heated at 37C for 10 min prior to loading on a 4%–20%
Tris-Glycine gel (Novex) and transferred to nitrocellulosemembranes. Fpnwas
detected with antibody H1. For JAK/STAT analysis, lysates were reduced
(50 mM DTT), heated at 95C for 3 min, run on a 4%–20% Tris-Glycine gel,
and transferred to nitrocellulose membranes. Phospho-JAK2, phospho-
STAT3, and phospho-STAT5 were detected using rabbit monoclonal anti-
bodies recognizing Y1007, Y705, and Y694, respectively (Cell Signaling).
Human cyclophilin B (rabbit polyclonal antibody, Abcam)was used as a protein
loading control. HRP-labeled, species-specific secondary antibodies were
used for detection (Cell Signaling).
siRNA Knockdown
293 T-REx/Fpn cells were reverse transfectedwith 20 nMSLC40A1 (Invitrogen
#HSS121213), cyclophilin B (QIAGEN, custom), or All Stars negative control916 Cell Metabolism 15, 905–917, June 6, 2012 ª2012 Elsevier Inc.(QIAGEN #1027281) siRNAs using RNAiMAX transfection reagent (Invitrogen).
Cells were induced to express Fpn with doxycycline immediately before trans-
fection. Lysates were made 48 hr after transfection. Protein (20 mg) from each
sample was tested by western analysis as described.
STAT Nuclear Translocation Assays
Cells were treated with varying concentrations of Hepc or the following control
cytokines: recombinant hu IL-6 + 26 nM soluble IL-6Ra (R&D Systems, 293
T-Rex/Fpn), recombinant hu PRL (BioVendor Laboratories, T47D cells),
recombinant hu Epo (Amgen, UT-7/Epo cells). All treatments (30 min) were
followed by fixation with formaldehyde (ThermoFisher) and permeabilization
with methanol. Phospho-STAT proteins were detected with the primary anti-
bodies used for western analysis and a goat anti-rabbit-Alexa Fluor 647
secondary antibody (Invitrogen). Nuclei were stained with Hoechst 33342.
For JAK inhibitor assays, cells were pretreated with varying concentrations
of inhibitors for 30 min prior to addition of control cytokines (at concentrations
corresponding to the EC90 for translocation in each cell line) or Hepc for an
additional 30 min. Nuclear phospho-STAT proteins were detected as
described. Each cell line was also assessed for cell-surface Fpn; cells were
pretreated with inhibitors for 30 min followed by 3 hr of treatment with Hepc.
Cells were imaged and cell-surface Fpn was detected on live cells as
described.
In Vivo JAK2 Inhibitor Assay
Groups of 12-week-old female C57BL/6 mice (Harlan Laboratories) were
dosed for 15 min with either a JAK2-selective or a pan-JAK small molecule
vehicle inhibitor (100 mg/kg, PO), or vehicle control prior to i.p. administration
of 50 mg Hepc or carrier. Mice were euthanized 90 min later, and blood was
collected by cardiac puncture for plasma iron determination using an Olympus
AU400 clinical chemistry analyzer (Olympus Diagnostics). Anti-Hepc antibody
(2 mg, subcutaneous) was administered 24 hr before Hepc dosing. Mice were
maintained on a normal diet (Teklad 2020X, 200 mg/kg iron). The research and
all technical procedures performed on animals under this study are approved
by the Institutional Animal Care and Use Committee (IACUC) for Amgen.
Animals are housed in an Association for the Assessment and Accreditation
of Laboratory Animal Care accredited facility and are cared for according to
standards established in the Guide for the Care and Use of Laboratory
Animals, eighth edition, written by a subcommittee of the National Research
Council at the Institute for Laboratory Animal Research.
Whole-Blood Ex Vivo Phospho-STAT5 Flow Cytometry Assay
Whole blood from JAK2 inhibitor and control groups of C57BL/6mice was har-
vested. Each sample was stimulated ex vivo with 1 ng/mL mouse GM-CSF
(Amgen) in RPMI for 30 min at 37C, 5% CO2, fixed with BD Fix-Lyse buffer
(BD Biosciences), permeabilized with 90% MeOH, and stored overnight at
80C. Fixed cells were blocked with mouse Fc block (purified rat anti-mouse
CD16/CD32, BD Biosciences) and stained with CD11b-PE and pSTAT5-Alexa
Fluor 647 (Y694) antibodies (both from BDBiosciences). Events were acquired
with FACSCalibur and analyzed with CellQuest. The graph represents the
geometric mean of phospho-STAT5 staining in the CD11b-gated granulo-
cyte/monocyte whole-blood population.
Ferritin Immunofluorescence
Cells were induced overnight or left uninduced. The next day, induction
medium was replaced with assay medium ±10 mM ferric citrate, ±2.5 mM
Hepc. After 16 hr, cells were fixed with 3.7% formaldehyde solution, permea-
bilized with 0.5% Triton X, and stained with a biotinylated anti-human ferritin
antibody (Lifespan) followed by streptavidin-Alexa Fluor 555 (Invitrogen).
Nuclei were stained with Hoechst dye, and ferritin was quantitated by image
analysis.
Statistical Analysis
All in vitro assay data are presented as means ±SD. Statistical significance
for Figure 2 and Figure 7 was determined using Statistical Analysis System
(SAS) version 9.1 with a mixed effect model (standard model for comparing
data derived from multiple assays performed on different days). Dunnett’s
post-hoc test was then used to compare cell-surface Fpn or intracellular
ferritin in cells expressing WT and mutant Fpn. In vivo assay data (Figure 6)
Cell Metabolism
Mechanism of Ferroportin Internalizationare presented as means ±SEM. Statistical significance was determined by
one-way ANOVA with Dunnett’s post hoc test.
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